Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.58 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 2/20 | 0.48 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862097 | 0.95 | ESR1 (0.52) | ESR1ESR2MAPTSMN1; SMN2TP53 | |
| SCHEMBL3861662 | 0.93 | ESR1 (0.60) | ESR1ESR2CYP26A1MIFCYP24A1 | |
| SCHEMBL9054865 | 0.91 | ESR1 (0.60) | ESR1ESR2CYP26A1MIFCYP24A1 | |
| SCHEMBL9571848 | 0.91 | ESR1 (0.51) | ESR1ESR2CYP26A1MIFMAPT | |
| SCHEMBL7107472 | 0.90 | ESR1 (0.52) | ESR1ESR2CYP26A1MIFCYP24A1 | |
| SCHEMBL7108932 | 0.90 | ESR1 (0.52) | ESR1ESR2CYP26A1MIFCYP24A1 | |
| SCHEMBL3976908 | 0.89 | ESR1 (0.55) | ESR1ESR2MIFMAPTSMN1; SMN2 | |
| SCHEMBL7942846 | 0.88 | ESR1 (0.51) | ESR1ESR2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL7110390 | 0.86 | ALDH1A1 (0.51) | ESR1ESR2MAPTSMN1; SMN2TP53 | |
| SCHEMBL11187364 | 0.86 | ESR1 (0.55) | ESR1ESR2MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-7501441-B1 | Naphthyl compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501441-B1 | Naphthyl compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | disclosed |
| US-5658931-A | ADMINISTERING A MIXTURE OF ANTIESTROGENS | ELI LILLY AND COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5554628-A | A 1-(4-ALKOXYPHENYL-)NAPHTHALENE COMPOUND | ELI LILLY AND COMPANY (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1996009052-A1 | A METHOD FOR INHIBITING MAMMALIAN BREAST CARCINOMA WITH TAMOXIFEN, AND ANALOGS THEREOF, AND CERTAIN NAPHTHYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996009039-A1 | NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0524742-B1 | Benzo(a)fluorene compounds | LILLY CO ELI (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5484796-A | Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting aortal smooth muscle cell proliferation | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
| US-5484795-A | Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting restenosis | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
| US-4400543-A | ANTIFERTILITY AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-23 | — | — | US | disclosed |
| US-4323707-A | USEFUL FOR AMIMALS, AROYL-PHENYL-NAPHTHALENES OR DIHYDRONAPHTHALENES | ELI LILLY AND COMPANY (US) | 1982-04-06 | — | — | US | disclosed |
| US-4230862-A | 3-PHENYL-4-AROYL-1,2-DIHYDRONAPHTHALENES AND 1-ARYOYL-2-PHENYLNAPHTHALENES | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885CYP26A1 87/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885CYP26A1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.